Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Studies from P.U. Malmstrom and colleagues provide new data on bladder cancer
June 9th, 2009
According to recent research from Melton Mowbray, the United Kingdom, "A decision analytic model was established to estimate the budget impact on the Swedish health service of using hexaminolevulinate (HAL) in conjunction with white light cystoscopy (WLC) in the management of bladder cancer for 1 year following initial diagnosis. Flowcharts were developed to represent the diagnostic and treatment pathways for each of four risk groups for non-muscle-invasive bladder cancer (NMIBC), as defined by risk of tumour recurrence and progression." "Flowcharts were based on European Association of Urology Guidelines and adjusted to current Swedish clinical practice. The model...
Source: Cancer Weekly (2009-06-09)
|
